- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise | 1 | GlobeNewswire (USA) | ||
| 12.04. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.04. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 | 58 | GlobeNewswire (Europe) | PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases... ► Artikel lesen | |
| 03.04. | Lipella Pharmaceuticals Announces Type C Meeting For LP-10 | 1 | RTTNews | ||
| 03.04. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis | 65 | GlobeNewswire (Europe) | PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases... ► Artikel lesen | |
| 19.03. | Lipella Pharmaceuticals executive Kaufman buys $45k in stock | 1 | Investing.com | ||
| 15.03. | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.03. | LIPELLA PHARMACEUTICALS INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | Lipella Pharma's IND Application For LP-410 Gets FDA's Approval | 3 | RTTNews | ||
| 05.03. | FDA greenlights Lipella's oral GVHD treatment trial | 1 | Investing.com | ||
| 05.03. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline | 66 | GlobeNewswire (Europe) | PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases... ► Artikel lesen | |
| 27.02. | LIPELLA PHARMACEUTICALS INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.02. | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference | 1 | GlobeNewswire (USA) | ||
| 20.12.23 | Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished | 213 | GlobeNewswire (Europe) | PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates... ► Artikel lesen | |
| 22.11.23 | LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.11.23 | LIPELLA PHARMACEUTICALS INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.23 | Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD | 1 | Pharmaceutical Business Review | ||
| 10.11.23 | Lipella's oral GvHD drug candidate gets orphan designation | 1 | Seeking Alpha | ||
| 10.11.23 | Lipella Pharma: FDA Grants Orphan Designation For LP-310 To Treat Oral Graft-versus-Host Disease | 1 | RTTNews | ||
| 01.11.23 | LIPELLA PHARMACEUTICALS INC. - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,986 | +4,45 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,975 | -1,02 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,754 | -3,33 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,960 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 6,660 | -1,19 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,450 | -6,73 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 4,200 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio | HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop... ► Artikel lesen | |
| BIOMEA FUSION | 11,160 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen LIPELLA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,22 % bei einem Aktienkurs von 0,715 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
